Daniel J Hui

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7321408/publications.pdf

Version: 2024-02-01

35	3,603	361413	454955
papers	citations	20 h-index	30 g-index

35	35	35	3379
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Genomeâ€First Approach to Rare Variants in Dominant Postlingual Hearing Loss Genes in a Large Adult Population. Otolaryngology - Head and Neck Surgery, 2022, 166, 746-752.	1.9	3
2	Importance of Including Non-European Populations in Large Human Genetic Studies to Enhance Precision Medicine. Annual Review of Biomedical Data Science, 2022, 5, 321-339.	6.5	17
3	A unified framework identifies new links between plasma lipids and diseases from electronic medical records across large-scale cohorts. Nature Genetics, 2021, 53, 972-981.	21.4	17
4	Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. New England Journal of Medicine, 2017, 377, 2215-2227.	27.0	549
5	AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15029.	4.1	59
6	Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Molecular Therapy, 2013, 21, 1727-1737.	8.2	38
7	Enhanced T Cell Function in a Mouse Model of Human Glycosylation. Journal of Immunology, 2013, 191, 228-237.	0.8	20
8	Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys. Science Translational Medicine, 2013, 5, 194ra92.	12.4	267
9	A Novel Strategy to Circumvent Pre-Existing Humoral Immunity to AAV. Blood, 2012, 120, 2050-2050.	1.4	3
10	Cardiac Gene Transfer of Short Hairpin RNA Directed Against Phospholamban Effectively Knocks Down Gene Expression but Causes Cellular Toxicity in Canines. Human Gene Therapy, 2011, 22, 969-977.	2.7	43
11	Safety and Efficacy of Subretinal Readministration of a Viral Vector in Large Animals to Treat Congenital Blindness. Science Translational Medicine, 2010, 2, 21ra16.	12.4	114
12	Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs. Molecular Therapy, 2010, 18, 1318-1329.	8.2	66
13	Proteasome Inhibitors Decrease AAV2 Capsid derived Peptide Epitope Presentation on MHC Class I Following Transduction. Molecular Therapy, 2010, 18, 135-142.	8.2	96
14	Peptide-Induced Antigen-Specific CD4+CD25+FoxP3+ T Cells Suppress Cytotoxicity T Cell Responses Directed Against the AAV Capsid.. Blood, 2010, 116, 3769-3769.	1.4	1
15	Intrinsically Hyperactive and Hyperproliferative CD8+ T Cells In Cmah-/- Mice as a Model of Human Gene Transfer Responses.. Blood, 2010, 116, 3773-3773.	1.4	2
16	Diverse IgG subclass responses to adenoâ€associated virus infection and vector administration. Journal of Medical Virology, 2009, 81, 65-74.	5.0	84
17	AAV-1â€“mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood, 2009, 114, 2077-2086.	1.4	248
18	Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. Journal of Clinical Investigation, 2009, 119, 1688-1695.	8.2	161

#	Article	IF	Citations
19	Suppression of CTL Responses against AAV-Capsid Epitopes by Peptide-Induced Regulatory T Cells.. Blood, 2009, 114, 377-377.	1.4	4
20	Proteasome Inhibitors Decrease AAV2 Capsid-Derived Peptide Epitope Presentation On MHC Class I Following Transduction.. Blood, 2009, 114, 695-695.	1.4	0
21	Reversal of Blindness in Animal Models of Leber Congenital Amaurosis Using Optimized AAV2-mediated Gene Transfer. Molecular Therapy, 2008, 16, 458-465.	8.2	236
22	Immunosuppression Modulates Immune Responses to AAV Capsid in Human Subjects Undergoing Intramuscular Gene Transfer for Lipoprotein Lipase Deficiency. Blood, 2008, 112, 822-822.	1.4	16
23	Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood, 2007, 110, 2334-2341.	1.4	218
24	CD8+ T-cell responses to adeno-associated virus capsid in humans. Nature Medicine, 2007, 13, 419-422.	30.7	629
25	Distinct Induction Patterns and Functions of Two Closely Related Interferon-inducible Human Genes, ISG54 and ISG56. Journal of Biological Chemistry, 2006, 281, 34064-34071.	3.4	148
26	AAV-2 Capsid-Specific CD8+ T Cells Limit the Duration of Gene Therapy in Humans and Cross-React with AAV-8 Capsid.. Blood, 2006, 108, 455-455.	1.4	2
27	Conserved Amino Acid Sequences in Parvovirus B19 and Adeno-Associated Virus Stimulate Functionally Cross-Reactive CD8 T Cells.. Blood, 2006, 108, 3269-3269.	1.4	0
28	A Novel Splenocyte Approach for Characterizing T Cell Responses to Adeno-Associated Virus in the Normal Population: Implications on Gene Transfer.. Blood, 2006, 108, 3258-3258.	1.4	0
29	Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Molecular Therapy, 2005, 12, 1023-1033.	8.2	85
30	Mouse p56 Blocks a Distinct Function of Eukaryotic Initiation Factor 3 in Translation Initiation. Journal of Biological Chemistry, 2005, 280, 3433-3440.	3.4	74
31	T Cell Responses to AAV Vector Capsid Limit the Duration of Transgene Expression in Humans after Liver-Directed Gene Therapy.. Blood, 2005, 106, 3055-3055.	1.4	0
32	Characterization of the Immune Response to Canine Factor IX Following AAV-Mediated Intravascular Gene Delivery to Skeletal Muscle in Hemophilia B Dogs.. Blood, 2005, 106, 1297-1297.	1.4	0
33	Alpha Interferon Induces Distinct Translational Control Programs To Suppress Hepatitis C Virus RNA Replication. Journal of Virology, 2003, 77, 3898-3912.	3.4	211
34	Viral Stress-inducible Protein p56 Inhibits Translation by Blocking the Interaction of eIF3 with the Ternary Complex eIF2Â·GTPÂ·Met-tRNAi. Journal of Biological Chemistry, 2003, 278, 39477-39482.	3.4	139
35	Carboxylmethylation of the Î² Subunit of xENaC Regulates Channel Activity. Journal of Biological Chemistry, 1998, 273, 28746-28751.	3.4	53